Quick Take
- MediBuddy FY25 revenue rose 12.3% YoY to Rs 743 Cr total income (operating revenue: Rs 724.6 Cr).
- Net loss fell 36.5% to Rs 137 Cr in FY25, with expenses flat at Rs 879 Cr.
- MediBuddy spent Rs 1.21 per rupee earned in FY25, improving from Rs 1.36 in FY24.
MediBuddy FY25 revenue reached Rs 743 Cr in total income — comprising Rs 724.6 Cr in operating revenue and Rs 18.42 Cr from non-operating sources — marking a 12.3% year-on-year increase from Rs 645.4 Cr in operating revenue in FY24, according to its consolidated financial statements filed with the Registrar of Companies (RoC). The Bengaluru-based digital healthcare platform, operated by Phasorz Technologies Private Limited, simultaneously cut its net loss by 36.5% to Rs 137 Cr from Rs 215.7 Cr in FY24 — achieving this on flat total expenditure of Rs 879 Cr.
The combination of accelerating revenue and controlled costs is producing the financial signature every loss-making startup wants to show: operating leverage beginning to work.
StartupFeed Insight
MediBuddy’s most important FY25 metric is not the revenue headline — it is the unit economics shift from Rs 1.36 to Rs 1.21. That 11% improvement in cost-per-rupee-earned, achieved on flat total expenses, signals that the company’s network of 7,000 hospitals, 3,000 diagnostic centres, and 2,500 pharmacies is starting to generate operating leverage. The diagnostic and allied services cost base grew only 5.3% while revenue grew 12.3% — a widening gap that compounds favourably as the 30 million user base deepens engagement. The structural advantage MediBuddy holds over standalone telemedicine or e-pharmacy players is its integrated model: one platform covering consultation, diagnosis, medicine delivery, surgery, and insurance. That breadth is what creates the repeat revenue needed to reach break-even.
MediBuddy FY25 Revenue and Cost Breakdown
| Metric | FY25 | FY24 | Change |
|---|---|---|---|
| Operating Revenue | Rs 724.6 Cr | Rs 645.4 Cr | +12.3% YoY |
| Non-Operating Income | Rs 18.42 Cr | ~Rs 18 Cr | Flat; FD interest + investments |
| Total Income | Rs 743 Cr | ~Rs 663.5 Cr | +12% YoY |
| Cost of Services (materials) | Rs 333 Cr | Rs 316 Cr | +5.3% YoY — 38% of total expenses |
| Employee Benefits | Rs 176.8 Cr | ~Rs 163 Cr | +8% YoY (incl. Rs 6 Cr ESOP) |
| Sales Payouts | Rs 155.47 Cr | ~Rs 167 Cr | -7% YoY — efficiency gain |
| Safety and Security | Rs 42.5 Cr | N/A | — |
| IT Infrastructure | Rs 32.5 Cr | N/A | — |
| Other Overheads (legal, advertising, D&A, finance) | Rs 138.7 Cr | N/A | — |
| Total Expenditure | Rs 879 Cr | Rs 879 Cr | Flat YoY |
| Net Loss | Rs 137 Cr | Rs 215.7 Cr | -36.5% YoY |
| EBITDA Margin | -14% | -26% | +12 percentage points YoY |
| Unit Economics (cost per Re 1 earned) | Rs 1.21 | Rs 1.36 | Improved 11% |
Two line items in the expense breakdown carry the clearest strategic signal. Sales payouts — commissions paid to distribution agents — fell 7% year on year, even as revenue grew 12.3%. That inversion shows that MediBuddy’s network is generating repeat and organic revenue that requires less commission-driven acquisition. The cost of services grew only 5.3%, well below the 12.3% revenue growth rate, confirming that network capacity is absorbing incremental volume without proportional cost increases.
About MediBuddy
MediBuddy, operated by Phasorz Technologies Private Limited, is one of India’s leading digital healthcare platforms offering end-to-end services including online and offline doctor consultations, medicine delivery, diagnostic testing, elective and non-elective surgeries, and health insurance. Founded in 2013 and headquartered in Bengaluru, the company is co-founded and led by CEO Satish Kannan and CTO Enbasekar Dinadayalan. MediBuddy operates across a network of 7,000 hospitals, 3,000 diagnostic centres, and 2,500 pharmacies, serving approximately 30 million users through a panel of around 90,000 doctors. The company has raised over $190 Mn in total funding.
Is MediBuddy Profitable in FY25?
No — MediBuddy remains loss-making, reporting a net loss of Rs 137 Cr in FY25. However, the trajectory is the most important indicator at this stage, and it is clearly positive. Three data points define where the company stands.
First, the EBITDA margin improved from -26% in FY24 to -14% in FY25 — a 12 percentage point swing in a single year. Second, total expenditure held flat at Rs 879 Cr despite 12% revenue growth, proving that cost discipline is not being sacrificed for growth. Third, the unit economics shift from Rs 1.36 to Rs 1.21 per rupee earned represents the kind of structural improvement that compounds: each percentage point improvement in unit economics at MediBuddy’s scale moves the net loss figure by a meaningful amount.
How Does MediBuddy Compare to Other Indian Healthtech Platforms?
| Platform | Model | FY25 Revenue* | Differentiator |
|---|---|---|---|
| MediBuddy | Integrated: consult + diagnostics + pharmacy + insurance | Rs 743 Cr (total income) | 30 Mn users, 90,000 doctors, 7,000 hospitals |
| Practo | Doctor discovery + teleconsultation + B2B software | Not publicly disclosed | Doctor management software; international presence |
| Tata 1mg | E-pharmacy + diagnostics + teleconsultation | Not separately disclosed (part of Tata Digital) | Tata brand trust; e-pharmacy scale |
| PharmEasy | E-pharmacy + diagnostics | Declining (company restructuring) | Scale in e-pharmacy; facing profitability pressure |
*FY25 revenue figures for peers are either not publicly disclosed or require verification. MediBuddy figure from RoC filings.
MediBuddy’s structural advantage over standalone telemedicine or e-pharmacy players is breadth: one platform covering the full patient journey from consultation to diagnosis, medicine delivery, surgery, and insurance. That breadth generates recurring cross-sell revenue at low marginal cost — the key to the path to profitability that single-vertical platforms cannot replicate easily.
What’s Next
MediBuddy’s FY26 report will be the decisive indicator. If the company can sustain 10-15% revenue growth while keeping expenses flat — or achieving a slight reduction in sales payouts — the EBITDA margin could reach -5% to -8% by FY26 end, making break-even a near-term reality rather than a medium-term aspiration. Watch for any announcement of a pre-IPO fundraise or a new corporate health insurance partnership that would accelerate the per-user revenue metric. A Series D or pre-IPO round is the most likely next capital event.
Will MediBuddy be the first fully integrated Indian digital healthcare platform to reach EBITDA break-even at scale?
Frequently Asked Questions
How much revenue did MediBuddy report in FY25?
MediBuddy FY25 revenue totalled Rs 743 Cr in total income, comprising Rs 724.6 Cr in operating revenue (up 12.3% year on year from Rs 645.4 Cr in FY24) and Rs 18.42 Cr in non-operating income from fixed deposit interest, investment returns, and other miscellaneous sources. Revenue from the company’s core healthcare services — including doctor consultations, diagnostic testing, medicine delivery, and health insurance — accounted for Rs 722 Cr of the operating revenue figure.
Is MediBuddy profitable in FY25?
MediBuddy is not yet profitable. The company reported a net loss of Rs 137 Cr in FY25, down 36.5% from Rs 215.7 Cr in FY24. Total expenditure held flat at Rs 879 Cr, while EBITDA margin improved from -26% to -14% year on year. Unit economics improved from Rs 1.36 per rupee earned to Rs 1.21, reflecting genuine cost discipline and emerging operating leverage from the platform’s network of 7,000 hospitals, 3,000 diagnostic centres, and 2,500 pharmacies.
What does MediBuddy do and who are its founders?
MediBuddy, operated by Phasorz Technologies Private Limited, is one of India’s leading digital healthcare platforms offering end-to-end services including online and offline doctor consultations, medicine delivery, diagnostic testing, elective and non-elective surgeries, and health insurance. Founded in 2013 and headquartered in Bengaluru, the company is co-founded and led by CEO Satish Kannan and CTO Enbasekar Dinadayalan. It serves approximately 30 million users through a network of around 90,000 doctors, 7,000 hospitals, 3,000 diagnostic centres, and 2,500 pharmacies. MediBuddy has raised over $190 Mn in total funding.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. StartupFeed and its authors are not SEBI-registered investment advisors. The analysis above is based on publicly available information and should not be the sole basis for any investment decision. Please consult a SEBI-registered financial advisor before making investment decisions.
